Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 3/20 | 0.61 |
| ▸ | CASP3 | P42574 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.52 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30977677 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29366757 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29613402 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL12537019 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL1486216 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29907974 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29352409 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29519824 | 0.95 | MDM4 (0.57) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL6742006 | 0.92 | MDM4 (0.55) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29451083 | 0.91 | CASP3 (0.59) | MDM4TP53CASP3KMT2AMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108047268-B | 1-aza-5-gera-5-alkyl bicyclo [3.3.3] undecane compound, synthesis method and application | 中国科学技术大学 | 2020-05-01 | — | — | CN | claimed |
| EP-3473249-A1 | CROSSLINKABLE DENDRIMERS | Wayne State University (US) | 2019-04-24 | — | — | EP | claimed |
| CN-108047268-A | A kind of miscellaneous two ring of -5- alkyl [3.3.3] the hendecane class compound of 1- azepines -5- germanium, synthetic method and application | 中国科学技术大学 | 2018-05-18 | — | — | CN | claimed |
| CN-107176975-A | A kind of method of synthesis in solid state Gonadorelin | 丹东中科润华生物科技有限公司 | 2017-09-19 | — | — | CN | claimed |
| US-20170028075-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | Ashvattha Therapeutics, Inc. | 2017-02-02 | — | — | US | claimed |
| US-9526794-B2 | Injectable dendrimer hydrogel nanoparticles | WAYNE STATE UNIVERSITY (US) | 2016-12-27 | — | — | US | claimed |
| US-20130136697-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | NATIONAL INSTITUTES OF HEALTH (US) | 2013-05-30 | — | — | US | claimed |
| EP-2552458-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | Wayne State University (US) | 2013-02-06 | — | — | EP | claimed |
| WO-2011123591-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | WAYNE STATE UNIVERSITY (US) | 2011-10-06 | — | — | WO | claimed |
| CN-101224306-B | Folic acid-polypeptide compound-mediated targeting anti-tumor prodrug and preparing method thereof | UNIV SUN YAT SEN | 2011-04-20 | — | — | CN | claimed |
| CN-100590068-C | Method for preparing primary amine carbon nano tube | UNIV TONGJI | 2010-02-17 | — | — | CN | claimed |
| US-20250288587-A1 | Methods of Treating Fibrosis | ATHIRA PHARMA, INC. (US) | 2025-09-18 | — | — | US | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-20250275976-A1 | Methods of Treating Neuroinflammatory Conditions | ATHIRA PHARMA, INC. (US) | 2025-09-04 | — | — | US | disclosed |
| EP-4581035-A1 | EXATECAN-DERIVED TOPOISOMERASE-1 INHIBITORS PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| US-4960881-A | REACTING AMINO ACID WITH ALPHA-CHLORINATED CARBONATE IN SOLVENT IN PRESENCE OF ACID SCAVENGER | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1990-10-02 | — | — | US | disclosed |
| EP-0154581-B1 | ALPHA-CHLORINATED CARBONATES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION TO THE PROTECTION OF AMINIC FUNCTIONS IN AMINO ACIDS | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1988-06-08 | — | — | EP | disclosed |
| US-4652665-A | BLOCK AMINE FUNCTION OF AMINO ACIDS; PEPTIDE SYNTHESIS | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1987-03-24 | — | — | US | disclosed |
| CN-85101227-A | The preparation method of novel alpha-chlorinated carbonates and application | — | 1987-01-24 | — | — | CN | disclosed |
| EP-0154581-A1 | Alpha-chlorinated carbonates, process for their preparation and their application to the protection of aminic functions in amino acids | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1985-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170028075-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | PAM, UACA, FLT1 | MDM4 3299/4885TP53 2320/4885CASP3 1763/4885 |
| US-20250288587-A1 | Methods of Treating Fibrosis | HDGF, HGF, MMP1 | MDM4 4049/4885TP53 1904/4885CASP3 675/4885 |
| US-20250275976-A1 | Methods of Treating Neuroinflammatory Conditions | HGF, HDGF, NGF | MDM4 3540/4885TP53 3142/4885CASP3 424/4885 |
| US-20130136697-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | UACA, PAM, JAK3 | MDM4 3016/4885TP53 3102/4885CASP3 1280/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | MDM4 3559/4885TP53 2654/4885CASP3 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.